HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

von Willebrand factor drug combination factor VIII

Subscribe to New Research on von Willebrand factor drug combination factor VIII

Share|Follow on Twitter

a plasma-derived dual FVIII/VWF concentrate

Also Known As:

factor VIII, von Willebrand factor drug combination; Alphanate; factor VIII - von Willebrand factor; haemate P

Networked: 132 relevant articles (11 outcomes, 16 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Franchini, Massimo: 5 articles (01/2010 - 11/2003)
2.	Federici, Augusto B: 4 articles (05/2008 - 03/2003)
3.	Federici, A B: 4 articles (02/2004 - 03/2000)
4.	Tagliaferri, Annarita: 3 articles (01/2010 - 11/2003)
5.	Auerswald, Günter: 3 articles (05/2008 - 04/2002)
6.	Budde, Ulrich: 3 articles (01/2007 - 04/2002)
7.	Berntorp, Erik: 2 articles (11/2009 - 05/2008)
8.	Berntorp, E: 2 articles (11/2008 - 01/2007)
9.	Mannucci, Pier M: 2 articles (05/2008 - 01/2002)
10.	Kreuz, Wolfhart: 2 articles (05/2008 - 04/2002)

Related Diseases

1.	Hemorrhage 01/15/2002 - "A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate for treatment of bleeding and surgical prophylaxis. " 09/01/2001 - "Early transfusion of factor VIII/von Willebrand factor concentrates seems to be effective in the treatment of gastrointestinal bleeding in patients with von Willebrand type III disease." 05/01/2008 - "Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for the treatment of HA-associated bleeding. " 07/01/2007 - "Fifty-nine patients were treated with Haemate P because of 280 spontaneous bleeding episodes. " 01/01/2006 - "Long-term prophylaxis with Haemate P has been shown to be safe, effective (also in terms of quality of life) and cost saving in this patient with severe gastrointestinal bleeding due to MVA and VWD." Order ALL the reference details at left...
2.	von Willebrand Diseases (von Willebrand's Disease) 11/01/2002 - "Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study." 12/01/2007 - "Recently, three multicentre prospective international studies have been carried out to evaluate the clinical efficacy and safety of Fanhdi [high-purity, double-inactivated plasma-derived factor VIII/von Willebrand factor (VWF) concentrate] in patients with von Willebrand's disease (VWD). " 04/01/2005 - "Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys." 06/01/1982 - "These studies provide evidence that the different subtypes of von Willebrand's disease represent distinct abnormalities of factor VIII/von Willebrand factor. " 08/01/1981 - "This study provides a model for understanding some of the normal structure-function relationships of the normal factor VIII/von Willebrand factor protein and the defect(s) in a variant form of von Willebrand's disease. " Order ALL the reference details at left...
3.	Hemophilia A (Haemophilia) 04/01/2005 - "The advent of virally inactivated factor VIII/von Willebrand factor (FVIII/VWF) concentrates, originally developed for the treatment of patients with hemophilia, provided improved therapy for VWD. " 01/01/2010 - "Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor." 03/01/2008 - "The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile." 07/01/2007 - "DESIGN AND METHODS: A retrospective survey of data records was organized among ten Italian Hemophilia Centers in order to retrieve information on the clinical use of Haemate P. " 06/01/2003 - "The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients." Order ALL the reference details at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 05/01/2004 - "Fibrinogen, thrombocytes, factor VII, factor VIII, von Willebrand factor (vWF), thrombomodulin (TM), plasminogen activator inhibitor--type 1 (PAI-1), tissue-plasminogen activator (t-PA) and other haemostatic factors, were described as more or less helpful in estimation of risk of occurrence of coronary artery disease and its cardiovascular complications. " Order ALL the reference details at left...
5.	Thrombosis (Thrombus) 11/01/1984 - "Thus, Factor VIII/von Willebrand factor (VIII/VWF) may mediate not only the adhesion of platelets to subendothelium but also platelet-platelet attachments necessary for normal thrombus development. " 11/01/2008 - "Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. " 07/31/1987 - "Platelet-membrane receptor inhibition to the fibrinogen receptor, factor VIII-von Willebrand factor or both may be necessary acutely to sufficiently reduce acute platelet-thrombus deposition." 07/01/1987 - "To determine if factor VIII-von Willebrand factor (vWF) complex is involved in the thrombosis associated with asparaginase-prednisone-vincristine induction therapy for acute lymphoblastic leukemia, plasma vWF was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis and crossed immunoelectrophoresis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	von Willebrand factor drug combination factor VIII
2.	von Willebrand Factor
3.	Factor VIII (Coagulation Factor VIII)
4.	Deamino Arginine Vasopressin (Desmopressin)
5.	Fibrinogen (Factor I)
6.	Factor VII (Proconvertin)
7.	Plasminogen Activators (Plasminogen Activator)
8.	Tissue Plasminogen Activator (Alteplase)
9.	Thrombomodulin
10.	Antigens

Related Therapies and Procedures

1.	Minor Surgical Procedures (Minor Surgery)
2.	Intravenous Infusions
3.	Lithotripsy (Extracorporeal Shockwave Lithotripsy)
4.	Light Coagulation

blog comments powered by Disqus

TREATMENT OPTIONS
for Hemorrhage,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3104 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>